Blog
Investor NexPoint has threatened to prevent the $462 million sale of Paratek
Source – Paratek Pharmaceuticals On 29 June, Paratek Pharmaceuticals is scheduled to hold its annual meeting, but a contentious situation ...
Dementia Solutions: Eisai, Gates, UK Health & Univ. Edinburgh
Source – Eisai On June 29, 2023, Eisai, Gates Ventures, Health Data Research UK, LifeArc, and The University of Edinburgh ...
Real Testimonials from Families Affected by CMV: Taking Action and Raising Awareness
Source – Moderna In 2011, Ayako Kamei, a Principal Scientist at Moderna Enzymatics, experienced the joy of welcoming her second ...
The pipeline for RSV, influenza, meningitis, and pneumococcal disease vaccines raises the bar
Source – Sanofi On June 29, 2023, Sanofi is hosting an investor event focused on its Vaccines pipeline, featuring key ...
Pediatric Growth Hormone Deficiency Long-Acting Once-Weekly Treatment NGENLA by Pfizer Receives FDA Approval
Source – Pfizer On 29 June 2023, Pfizer and OPKO Health jointly announced that the US Food and Drug Administration ...
Combining mitazalimab with chemotherapy demonstrates significant antitumor activity in metastatic pancreatic ductal adenocarcinoma
Source – Alligator Bioscience On June 26, 2023 the combination of mitazalimab, a novel CD40 monoclonal antibody agonist, with chemotherapy ...
Initiation of Treatment with TTI-101, Either Alone or in Combination with Standard Targeted Therapy, in Advanced Hepatocellular Carcinoma
Source – Tvardi Therapeutics On June 22, 2023 the initial administration of TTI-101, either as a monotherapy or in combination ...
National Institute for Health and Care Excellence remains skeptical about the effectiveness of Mounjaro for diabetes
Eli Lilly has received positive data for its experimental obesity therapies, but in the UK, it faced a setback as ...
A recent study demonstrates the efficacy of the digital Dario tool in managing severe diabetes
Source – DarioHealth A joint effort between DarioHealth and Sanofi has yielded promising results in a real-world study presented at ...
The FDA expedites the development of GSK’s vaccine for gonorrhea
Source – GSK GSK’s vaccine for gonorrhea has received a fast-track designation from the FDA, signaling its potential to combat ...
UCB has achieved a long-awaited victory as the FDA grants approval for the myasthenia gravis drug Rystiggo
Source – UCB On 27 June 2023, UCB faced regulatory challenges in the United States for the second consecutive year, ...
Eli Lilly agrees to pay $2.4 million to resolve an age discrimination lawsuit filed by a federal agency
Eli Lilly has settled a significant lawsuit related to age discrimination allegations. The company will pay $2.4 million as part ...
Regeneron has faced an unexpected rejection from the FDA for its high-dose version of Eylea due to manufacturing challenges
Source – Regeneron Regeneron’s highly anticipated high-dose version of Eylea has suffered an unexpected setback as the FDA rejected its ...
AstraZeneca Invests $400M in Reforestation and Biodiversity
Source – AstraZeneca AstraZeneca has made a significant announcement of a $400 million investment in its global AZ Forest program, ...
Epcoritamab Shows Promise in Follicular Lymphoma Trial
Source – Abbvie On 28 June 2023, AbbVie in collaboration with Genmab, disclosede the initial findings of the Phase I/II ...
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
Source – Pfizer On 28 June 2023, Pfizer announced that the US Food and Drug Administration (FDA) and the European ...
Repercussions of Oncologic Drug Shortages Shift Responsibility to Major Payers
Introduction In the realm of healthcare, access to life-saving medications is of paramount importance. Unfortunately, the occurrence of oncologic drug ...
Promising Objective Response Rate (ORR) Observed in Phase II Trial of Envafolimab for Sarcoma
Source: TRACON Pharmaceuticals Positive findings from the ongoing Phase II ENVASARC trial (NCT04480502) demonstrate that envafolimab (KN035), either as a ...
Verona Pharma has recently filed a New Drug Application to FDA for the use of ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease
Source – Verona Pharma On June 27, 2023, Verona Pharma announced the submission of a New Drug Application (NDA) to ...
FDA has outlined its perspective on clinical trials involving psychedelic drugs
The FDA has released its inaugural guidance document regarding clinical trials involving psychedelic drugs, which represent a burgeoning field of ...
Novo Nordisk and Eli Lilly Drive Breakthroughs in Oral GLP-1 Treatments for Obesity at ADA Conference
Novo Nordisk and Eli Lilly showcased advancements in the development of oral GLP-1 treatments for Type II diabetes and obesity ...
Vertex and Lonza Partner for New Cell Therapy Manufacturing Facility, Creating Job Opportunities
Source – Vertex Pharmaceuticals With promising developments in its experimental cell therapy VX-880 for type I diabetes, Vertex Pharmaceuticals is ...
FDA’s Peter Marks Overrides Reviewers’ Rejection to Approve Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy
Despite the FDA review teams initially leaning against approving Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy, a memo reveals that ...
Lilly’s Retatrutide Shows Promising Phase II Results By Weight Reduction in Adults with Obesity and Overweight
Source – Eli Lilly On June 26, 2023, Eli Lilly and Company announced the release of new Phase II findings ...
Xigduo XR Receives Approval in China for the Treatment of Type II Diabetes in Adults
Source – AstraZeneca On June 27, 2023, AstraZeneca’s Xigduo XR, a once-daily fixed-dose combination of dapagliflozin and metformin hydrochloride extended-release, ...
Promising Phase IIb Results in Atopic Dermatitis: amlitelimab as a Groundbreaking Treatment
Source – Sanofi On June 27, 2023, Sanofi announced positive Phase IIb Results. Amlitelimab shows promise as a first-in-class investigational ...
Pfizer Shares Progress of Clinical Development Program for GLP-1-RA in Adults with Obesity and Type II Diabetes Mellitus
Source – Pfizer On June 26, 2023, Pfizer Provides Update on Clinical Development Program for GLP-1-RA in Obesity and Type ...
Promising Early Antitumor Activity of Camrelizumab Plus Famitinib in Advanced Melanoma
A Phase II trial presented at the 2023 ASCO Annual Meeting showed that combining the PD-L1 inhibitor camrelizumab with the ...
TAK-755 Prophylaxis Shows Promise in Managing cTTP: ISTH 2023 Congress Highlights
Source – Takeda On June 25, 2023, Takeda has shared promising interim findings from a global Phase III clinical trial ...
CMS unveils details of its registry strategy for drugs targeting Alzheimer’s disease
Centers for Medicare and Medicaid Services (CMS) reveals additional details regarding its controversial plan to mandate participation in a patient ...
